Tislelizumab (Anti-Programmed Cell Death Protein-1 (PD-1) Antibody) in MSI-H or dMMR Solid Tumors

NCT03736889 · clinicaltrials.gov ↗

PHASE2

Phase

RECRUITING

Status

200

Enrollment

INDUSTRY

Sponsor class

Conditions

MSI-H/dMMR Solid Tumors

Interventions

DRUG: Tislelizumab (BGB-A317)

Sponsor

BeiGene